Crossject Appoints New CFO to Accelerate ZEPIZURE Launch in the USA
Crossject has announced the appointment of Lionel Seltz as Chief Financial Officer. His arrival comes at an advanced stage of the company's development as it moves towards the registration and commercialization of ZEPIZURE®.
Leadership Transition
Lionel Seltz assumes his role as Chief Financial Officer of Crossject, succeeding in a position where the specialty pharmaceutical company is accelerating the valorization of its ZENEO® technology platform and preparing the regulatory, industrial, and international steps of its development, particularly in the United States. Prior to joining Crossject, Lionel Seltz served as CFO of North Europe at Antech Diagnostics, where he oversaw the finance function in multiple countries within a major international health sector organization. He has also held CFO and executive management positions in publicly traded and high-growth companies in the health and technology sectors.
Strategic Role in Growth
As Chief Financial Officer, Lionel Seltz will support the next growth phase of Crossject with a particular focus on financial strategy, funding optimization, operational performance, industrial scale-up, and international development.
